BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
- 10 September 2007
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 27 (9) , 1189-1197
Abstract
Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for treatment of multiple myeloma, and is currently being evaluated clinically in a range of solid tumours. The mechanisms underlying its cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX- and BAK-dependent cell death. These mechanisms are reviewed and the implications for favourable novel drug interactions are highlighted.Keywords
This publication has 122 references indexed in Scilit:
- Rapid Turnover of Mcl-1 Couples Translation to Cell Survival and ApoptosisJournal of Biological Chemistry, 2007
- Loss of Mcl-1 Protein and Inhibition of Electron Transport Chain Together Induce Anoxic Cell DeathMolecular and Cellular Biology, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cellsApoptosis, 2006
- Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitorsOncogene, 2005
- Endogenous association of Bim BH3‐only protein with Mcl‐1, Bcl‐xL and Bcl‐2 on mitochondria in human B cellsEuropean Journal of Immunology, 2005
- The mitochondrial calcium uniporter is a highly selective ion channelNature, 2004
- The Molecular Mechanism of Noxa-induced Mitochondrial Dysfunction in p53-Mediated Cell DeathJournal of Biological Chemistry, 2003
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001